2025
Phenotypic and genotypic characterization of Mycobacterium tuberculosis pyrazinamide resistance—India, 2018–2020
Tamilzhalagan S, Justin E, Selvaraj A, Venkateswaran K, Sivakumar A, Chittibabu S, McLaughlin H, Moonan P, Smith J, Suba S, Narayanan M, Ho C, Kumar N, Tripathy S, Shanmugam S, Hall-Eidson P, Ranganathan U. Phenotypic and genotypic characterization of Mycobacterium tuberculosis pyrazinamide resistance—India, 2018–2020. Frontiers In Microbiology 2025, 15: 1515627. PMID: 39845030, PMCID: PMC11750862, DOI: 10.3389/fmicb.2024.1515627.Peer-Reviewed Original ResearchPZA resistancePyrazinamide resistanceMultidrug resistanceDuration of tuberculosis treatmentWhole-genome sequencingPrevalence of mutationsSecond-line drugsPZA-resistant isolatesResistance-conferring mutationsGenome sequenceTB burden countriesLineage 2Genotypic characterizationResistance markersNovel mutationsPhenotypic resistanceMutational diversityDiagnostic accuracyTuberculosis treatmentAntituberculosis drugsCo-resistanceBurden countriesPyrazinamideMutationsTB prevention
2023
Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DM
Khera R, Dhingra L, Aminorroaya A, Li K, Zhou J, Arshad F, Blacketer C, Bowring M, Bu F, Cook M, Dorr D, Duarte-Salles T, DuVall S, Falconer T, French T, Hanchrow E, Horban S, Lau W, Li J, Liu Y, Lu Y, Man K, Matheny M, Mathioudakis N, McLemore M, Minty E, Morales D, Nagy P, Nishimura A, Ostropolets A, Pistillo A, Posada J, Pratt N, Reyes C, Ross J, Seager S, Shah N, Simon K, Wan E, Yang J, Yin C, You S, Schuemie M, Ryan P, Hripcsak G, Krumholz H, Suchard M. Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DM. BMJ Medicine 2023, 2: e000651. PMID: 37829182, PMCID: PMC10565313, DOI: 10.1136/bmjmed-2023-000651.Peer-Reviewed Original ResearchType 2 diabetes mellitusSecond-line treatmentCardiovascular risk groupsDiabetes mellitusCardiovascular diseaseAntihyperglycaemic drugsLine treatmentRisk groupsObservational Health Data SciencesGlucagon-like peptide-1 receptor agonistsElectronic health recordsSodium-glucose cotransporter 2 inhibitorsCalendar year trendsPeptide-1 receptor agonistsUS databaseOutcomes of patientsCotransporter 2 inhibitorsAdministrative claims databaseSecond-line drugsHealth recordsSodium-glucose cotransporter-2 inhibitorsMedication useMetformin monotherapyGuideline recommendationsOutcome measures
2018
Association of Hemoglobin A1c Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin
Vashisht R, Jung K, Schuler A, Banda J, Park R, Jin S, Li L, Dudley J, Johnson K, Shervey M, Xu H, Wu Y, Natrajan K, Hripcsak G, Jin P, Van Zandt M, Reckard A, Reich C, Weaver J, Schuemie M, Ryan P, Callahan A, Shah N. Association of Hemoglobin A1c Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin. JAMA Network Open 2018, 1: e181755. PMID: 30646124, PMCID: PMC6324274, DOI: 10.1001/jamanetworkopen.2018.1755.Peer-Reviewed Original ResearchConceptsDPP-4 inhibitorsDipeptidyl peptidase-4 inhibitorsFirst-line therapyPeptidase-4 inhibitorsSecond-line drugsType 2 diabetesMyocardial infarctionEye disordersKidney disordersDrug classesSecond-line treatment choiceTotal hemoglobinObservational Health Data SciencesSecond-line treatment optionNew-user cohort studyEffectiveness of sulfonylureasSecond-line treatmentHemoglobin A1c levelsUse of sulfonylureasHealth Data SciencesLarge international studyElectronic medical recordsRoutine medical practiceInsurance claims dataCohort study
2016
Second line drug susceptibility testing to inform the treatment of rifampin-resistant tuberculosis: a quantitative perspective
Kendall EA, Cohen T, Mitnick CD, Dowdy DW. Second line drug susceptibility testing to inform the treatment of rifampin-resistant tuberculosis: a quantitative perspective. International Journal Of Infectious Diseases 2016, 56: 185-189. PMID: 28007660, PMCID: PMC5576040, DOI: 10.1016/j.ijid.2016.12.010.Peer-Reviewed Original ResearchConceptsSecond-line drug susceptibility testingRifampin-resistant tuberculosisDrug susceptibility testingSecond-line drug resistanceDrug resistanceSusceptibility testingHigh-burden settingsSecond-line drugsDrug-resistant tuberculosisEffective regimensTreatment failureTreatment outcomesSmall incremental costEpidemiologic benefitsResistance amplificationPatientsTuberculosisIncremental costMost settingsWidespread implementationSettingRegimensPrevalence
2013
Impact of HIV drug resistance on virologic and immunologic failure and mortality in a cohort of patients on antiretroviral therapy in China
Liao L, Xing H, Su B, Wang Z, Ruan Y, Wang X, Liu Z, Lu Y, Yang S, Zhao Q, Vermund SH, Chen RY, Shao Y. Impact of HIV drug resistance on virologic and immunologic failure and mortality in a cohort of patients on antiretroviral therapy in China. AIDS 2013, 27: 1815-1824. PMID: 23803794, PMCID: PMC3694318, DOI: 10.1097/qad.0b013e3283611931.Peer-Reviewed Original ResearchConceptsCombination antiretroviral therapyHIV drug resistanceImmunologic failureHigh mortalityVirologic failureAntiretroviral therapyEmergence of HIVDRBaseline CD4 cell countDrug resistanceCD4 cell countCohort of patientsSecond-line drugsEnd of studyProportional hazards modelRural Chinese countiesHIVDR mutationsMedian timePatient adherenceKaplan-MeierChinese patientsRisk factorsHazards modelPatientsCell countMortality
2012
Linking Surveillance with Action against Drug-Resistant Tuberculosis
Cohen T, Manjourides J, Hedt-Gauthier B. Linking Surveillance with Action against Drug-Resistant Tuberculosis. American Journal Of Respiratory And Critical Care Medicine 2012, 186: 399-401. PMID: 22592806, PMCID: PMC3443807, DOI: 10.1164/rccm.201203-0394pp.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisForms of TBDrug-resistant TBManagement of patientsDrug-resistant tuberculosisSecond-line drugsEffective public health responseDrug susceptibility testingPublic health responseQuality-assured treatmentMDRTB treatmentIncident casesHigh burdenProgrammatic dataHealth responseDrug resistanceSusceptibility testingImproved surveillance methodsPopulation subgroupsSurveillance methodsSurveillance activitiesTuberculosisClear roleTreatmentRecent global estimates
2006
Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa
Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Friedland G. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. The Lancet 2006, 368: 1575-1580. PMID: 17084757, DOI: 10.1016/s0140-6736(06)69573-1.Peer-Reviewed Original ResearchConceptsDrug-resistant tuberculosisCo-infected patientsXDR tuberculosisMDR tuberculosisHIV co-infected patientsCulture-confirmed tuberculosisRecent hospital admissionTime of diagnosisSecond-line drugsDrug susceptibility testingCause of deathDate of deathHigh mortality rateAntiretroviral therapyMedian survivalHospital admissionSputum cultureHIV-1PatientsMortality rateHigh mortalityUrgent interventionTreatment programTuberculosisSusceptibility testingRepresentative drug susceptibility patterns for guiding design of retreatment regimens for MDR-TB.
Rich M, Socci A, Mitnick C, Nardell E, Becerra M, Bonilla C, Bayona J, Seung K, Furin J, Farmer P, Mukherjee J. Representative drug susceptibility patterns for guiding design of retreatment regimens for MDR-TB. The International Journal Of Tuberculosis And Lung Disease 2006, 10: 290-6. PMID: 16562709.Peer-Reviewed Original ResearchConceptsPrevious treatment exposureRetreatment regimensDrug susceptibility testingPatient populationDST patternsTreatment exposureGroup 1Likely effective drugsMDR-TB regimensSecond-line drugsDrug susceptibility patternsNational Tuberculosis ProgrammeDifferent patient populationsAnti-tuberculosis agentsIndividualized regimensMDR-TBTuberculosis ProgrammeEffective anti-tuberculosis agentsSusceptibility patternsDST resultsRegimensEffective drugsPatientsGroup 4Susceptibility testing
2005
Treatment of multiple drug-resistant tuberculosis (MDR-TB) in Iran
Mirsaeidi SM, Tabarsi P, Khoshnood K, Pooramiri MV, Rowhani-Rahbar A, Mansoori SD, Masjedi H, Zahirifard S, Mohammadi F, Farnia P, Masjedi MR, Velayati AA. Treatment of multiple drug-resistant tuberculosis (MDR-TB) in Iran. International Journal Of Infectious Diseases 2005, 9: 317-322. PMID: 16183321, DOI: 10.1016/j.ijid.2004.09.012.Peer-Reviewed Original ResearchConceptsMultiple drug-resistant tuberculosisMore second-line drugsDrug-resistant tuberculosis treatmentMDR-TB patientsMDR-TB treatmentMasih Daneshvari HospitalDrug-resistant tuberculosisSecond-line drugsAppropriate treatment regimensProbable cureDrug regimenTreatment regimenComplete followTreatment regimensTuberculosis treatmentPatientsAverage durationRegimenTreatmentDrugsCureRegimensAmikacinHospitalFollow
1995
Epilepsy Surgery: Removing the Thorn From the Lion's Paw
HOLLOWAY K, CORRIE W, WINGKUN E, JOHNSON M, KUTA A. Epilepsy Surgery: Removing the Thorn From the Lion's Paw. Southern Medical Journal 1995, 88: 619-625. PMID: 7777876, DOI: 10.1097/00007611-199506000-00004.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultBrain DiseasesChildCorpus CallosumElectrodes, ImplantedElectroencephalographyEpilepsies, PartialEpilepsy, Temporal LobeFollow-Up StudiesHematomaHumansMagnetic Resonance ImagingMiddle AgedMonitoring, PhysiologicPostoperative ComplicationsSubdural SpaceTemporal LobeVideotape RecordingConceptsLobe epilepsySecond-line drugsExtratemporal lobe epilepsyTemporal lobe epilepsyPrimary regimenSurgical resectionEpilepsy surgeryIntractable epilepsyPresurgical evaluationSeizure focusPatientsEpilepsySeizuresSignificant deficitsResectionPawsWorthwhile reductionPercentMedicationsMorbidityRegimenSurgery
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply